Dr. Eickelberg’s research focuses on the molecular events that initiate, perpetuate, or resolve tissue fibrosis. This is relevant to a number of important lung diseases, including idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension (PAH), or chronic lung allograft dysfunction (CLAD) after lung transplantation. Investigations from his group have identified and mechanistically interrogated TGF-beta and WNT signaling as a novel mechanism driving lung fibrogenesis. His studies have delineated in detail the components of the lung extracellular matrix in health and fibrosis, as well as immune cell populations that drive fibrosis in the lung. Most recently, these investigations enabled the stratification of fibrosis subtypes and, by identifying long-lived MZB1+ plasma cells in tissue fibrosis, uncovered a novel common mechanism of tissue fibrosis.
Oliver Eickelberg, MD